Circulating endothelial cells (CECs) are associated with neoangiogenesis in various malignant disorders. Using flow cytometry, we studied CECs in 128 patients with myelodysplastic syndrome (MDS). MDS patients had higher CEC levels than controls (Po0.001), and an inverse relationship was found between CECs and international prognostic scoring system risk (r ¼ À0.55, Po0.001). There was a positive correlation between marrow microvessel density and CECs, low-risk patients showing the strongest association (r ¼ 0.62, Po0.001). We calculated a progenitor-to-mature CEC ratio, which was higher in MDS patients than in healthy subjects (Po0.001), the highest values were found at diagnosis. CECs assessed by flow cytometry positively correlated with the ability to produce endothelial colony-forming cells in vitro (ECFCs; r ¼ 0.57, P ¼ 0.021), which was significantly higher in MDS patients than in controls (P ¼ 0.011). Fluorescence in situ hybridization analysis showed that a variable proportion of CECs (from 40 to 84%) carried the same chromosomal aberration as the neoplastic clone, while endothelial cells isolated from in vitro assays were negative. This study suggests that CECs reflect the abnormal angiogenesis found in MDS, especially in the early stages of the disease. The increased number of functional endothelial progenitor cells in MDS strengthens the rationale for therapeutic interventions aimed at restoring a normal interaction between hematopoietic progenitors and marrow microenvironment.
Introduction
Tumor growth and dissemination require active endothelial proliferation, a process referred to as neoangiogenesis. 1 Both tumor and endothelial cells play a central role in this process. It is well known that tumor cells can elicit the sprouting of new blood vessels from pre-existing capillaries by the active release of angiogenic factors. 2 Moreover, in some cases, cancer cells themselves are located in the wall of tumor blood vessels mimicking endothelial activities and functions. 3 In addition to these mechanisms, there is growing evidence that bone marrow-derived endothelial cells may contribute to tumor angiogenesis. 4, 5 In early embryo, vasculogenesis involves the differentiation of primitive endothelial precursors (also known as hemangioblasts) into mature endothelial cells. 1 In adult humans, circulating endothelial cells (CECs), which are mobilized from the bone marrow and transported through the bloodstream to become incorporated into the vascular bed, have been identified. 4 In several kinds of human cancer, there is an increased number of CECs that may participate in vessel formation and contribute to disease progression. [6] [7] [8] Recent findings indicate that variable proportions of CECs exhibit tumor-specific genetic aberration, suggesting a close relationship between these cells. 3, 9 In chronic myeloid leukemia, a progenitor cell that carries the BRC-ABL fusion gene, has hemangioblastic characteristics and is able to differentiate into malignant blood cells as well as into phenotypically defined endothelial cells has been identified. 10 Myelodysplastic syndromes (MDSs) are clonal disorders in which malignant transformation occurs at the level of a committed myeloid stem cell that can give rise to red cells, platelets and granulocytes. 11, 12 The biological hallmark of the myelodysplastic hematopoietic cells is a defective capacity for self-renewal and differentiation, resulting in ineffective hematopoiesis. The emergence of myelodysplastic clones is favored by a perturbed interaction between hematopoietic progenitors and marrow stromal microenvironment. 13 In addition, increased bone marrow angiogenesis may participate in the pathophysiology of these disorders. 14, 15 Preliminary data indicate that endothelial cells are increased in the peripheral blood (PB) of MDS patients, 16 but their biological characteristics and their possible relationship with the malignant clone remain to be clarified.
In the present study, we analyzed CECs by flow cytometry and correlated the results with clinical parameters and bone marrow vasculature in 128 patients with MDS. We also tested the in vitro ability of these cells to produce endothelial colonies and analyzed both purified CECs and endothelial colonies by fluorescence in situ hybridization (FISH) and PCR to clarify whether they are tumor-derived.
Materials and methods

Patients
This prospective, single-institution study enrolled 128 MDS patients followed at the Department of Hematology, Fondazione IRCCS Policlinico San Matteo and University of Pavia Medical School, Pavia, Italy. This study was approved by the local ethics committee, the procedures followed were in accordance with the Helsinki Declaration of 1975, as revised in 2000, and patients gave written informed consent. Ninety-six patients were evaluated at the time of diagnosis, whereas 32 were evaluated during the course of the disease (median time from diagnosis 41 months, range 14-135). Clinical and hematological characteristics of the patients are summarized in Table 1 . Cytological diagnosis of MDS was made according to the World Health Organization (WHO) classification by two independent cytologists. 17, 18 Cytogenetic analysis was performed at diagnosis, using standard G-banding with trypsin-Giemsa staining, and karyotypes were classified using the International System for Cytogenetic Nomenclature Criteria. The international prognostic scoring system (IPSS) was employed to define prognosis, according to Greenberg et al. 19 Control PB samples were obtained from 28 healthy individuals.
Flow cytometry analysis of CECs
Peripheral blood samples were stained within 3 h using a whole blood lysis technique (NH 4 Cl) according to standard procedures. 20 Multiparametric four-color flow cytometry acquisition was performed with a Coulter Epix XL flow cytometer (Beckman Coulter, Milan, Italy). At least 300 000 events were acquired for each sample. Data (collected in list mode) were analysed using the EXPO32 ADC software (Beckman Coulter). The monoclonal antibody panel employed was as follows: fluorescein isothiocyanate (FITC) anti-CD146 (Chemicon International, Milan, Italy); phycoerythrin (PE) anti-CD133 (Miltenyi Biotech, Bologna, Italy), anti-CD34 and anti-CD146 (Becton Dickinson, Milan, Italy); PE-Texas Red (ECD) anti-CD34 and anti-CD45 (CoulterInstrumentation Laboratory, Milan, Italy) and PE-cyanine 5 (PC5) anti-CD45 (Coulter). Isotype-matched negative controls were used in all assays. Endothelial cells were identified by the expression of specific marker CD146. 21, 22 Gating strategy to identify CECs was based on CD45 staining to exclude hematopoietic cells; CECs were identified in CD45À gate as CD146 þ /CD34 þ cells. CD133, an antigen gradually lost during endothelial cell differentiation, 23 was utilized to discriminate between endothelial progenitors and mature endothelial cells (Figure 1 ). The analysis was performed excluding cellular debris in a side scatter/forward scatter dot plot. The percentage of positive cells was calculated subtracting the value 
Immunomagnetic isolation and immunocytochemical analysis of CECs
Circulating endothelial cells were isolated, with some modifications, as previously described. 9, 24 Briefly, 30 ml PB was collected and CECs were isolated by immunomagnetic sorting with Dynabeads Pan Mouse IgG (Dynal A.S., Oslo, Norway) by a two-step approach. To eliminate hematopoietic cells, we first performed a negative selection with Dynabeads coated with FITC anti-CD45 (Coulter). CD45-negative cells were subsequently subjected to a positive selection with Dynabeads coated with PE anti-CD146 antibody (Becton Dickinson). For further characterization, sorted CD146 þ /CD45À cells were treated with DNase-containing buffer to detach beads from the cells, and then stained in separate experiments with FITC anti-CD14, anti-CD31 and anti-CD34 (Coulter); with anti-von Willebrand factor (Dako, Glostrup, Denmark) followed by FITC goat antimouse (Becton Dickinson); with biotin-conjugated anti-VEGFR-2 (Sigma, St Louis, MO, USA) followed by FITC-conjugated streptavidin (Molecular Probes, Eugene, OR, USA).
In vitro colony-forming unit-endothelial cell and endothelial colony-forming cell production by CECs
In vitro colony-forming unit-endothelial cell (CFU-EC) and endothelial colony-forming cell (ECFC) production by CECs was assessed according to Asahara et al. 25 and Ingram et al., For ECFC assay, 50-150 Â 10 6 PB MNCs were plated in collagen-coated six-well plates (BD Biosciences) in the presence of EBM2 medium supplemented with EGM2 SingleQuots (Cambrex Bio Science, Walkersville, MD, USA) and incubated at 37 1C and 5% CO 2 . After 2 days, nonadherent cells were collected and discarded, whereas adherent cells were kept in culture in the same conditions for up to 30 days, with medium change every 2 days. Colonies appeared starting from 9 days of culture and their number and size increased up to 30 days. ECFCs appeared as round-shapes cobblestone-like colonies of rapidly growing cells (Figure 2a 
FISH and PCR analysis of CECs and cultured endothelial cells
The following probes were used for hybridization: LSI EGR1 (5q31) spectrum orange/D5S721, D5S23(5p15.2) spectrum 
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MG Della Porta et al green dual-color probe; LSI D7S522 (7q31) spectrum orange/CEP7 spectrum green dual-color probe; and CEP 8 spectrum orange probe (Vysis, Abbott Park, IL, USA). A detailed description of the technique was previously reported. 9 Briefly, sorted CD146 þ /CD45À CECs as well as endothelial cells isolated from both CFU-ECs and ECFCs were fixed in acetone:methanol (19:1 v/v) and stored at À20 1C. Slides were washed, dehydrated in an ethanol alcohol series and air-dried. The slides were warmed and then immersed in a 70% formamide solution at 72 1C for 5 min and dehydrated again at À20 1C. Each probe (10 ml) was added to the slides, which were incubated overnight at 37 1C in a moist chamber. After posthybridization washing procedures, evaluation of FISH results was performed using a Nikon fluorescence-equipped microscope with a charge-coupled black and white camera device and appropriate hardware and software (Nikon, Florence, Italy). To prevent data misinterpretation due to inefficient hybridization, only areas with 480% of cells showing two control signals were analysed. To ensure better visualization of the images, pseudocolors were attributed to the background, the cells and the signals.
For PCR analysis, DNA from selected endothelial colonies from MDS with del5q31 was purified (Purgene DNA purification kit from Gentra Systems, Minneapolis, MI, USA). GenomiPhi DNA amplification method (Amersham Biosciences, Freiburg, Germany) was employed for whole genome amplification. DNA quality was assessed through gel electrophoresis and b-actin amplification. Genotyping of polymorphic loci was performed by amplification with primers labeled with fluorescent probes (ABI 5-Fam and Hex) followed by analysis on an ABI 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). The following markers of chromosome 5 covering the region 5q31 were investigated: AFM350YB1, D5S476, D5S414, D5S500, D5S1372 and D5S816.
Measurement of bone marrow microvessel density
Microvessel density (MVD) was assessed blindly in MDS patients as well as in marrows from control subjects with no evidence of marrow disease performed for diagnostic purpose. The 3 mm thick paraffin sections obtained from trephine bone marrow biopsies were immunostained with CD34 monoclonal antibody (clone: QB-End/10, Ylem, 1:100, pretreatment with citrate buffer 0.1 M, pH 6, in microwave oven, 2 cycles of 5 min at 400 W), using a Dako automated immunostainer (streptavidin-biotin-peroxidase method, chromogen: 3,3 0 dianimobenzidine tetrahydrochloride). All specimens were treated using identical procedures. The substitution of primary antibody with nonimmune mouse serum was used as negative control. Vascular structures were defined as groups of CD34 þ endothelial cells forming a structure with a discernible lumen, while CD34 þ blasts were defined as small-to medium-sized round cells, with scant cytoplasm, central nucleus and small nucleolus, showing membrane and cytoplasmic annular immunostaining. 14, 15 In each case, the absolute number of CD34 þ vascular structures was recorded in 10 randomly selected fields at Â 400 magnification; arterioles with media layer were excluded from the count, while sinusoids were included.
Statistical methods
Numerical variables are summarized by their median and ranges or by mean and standard deviation. Categorical variables are described by counts and relative frequencies. Analyses of variance comparing means between groups were performed to test each numerical parameter for differences between MDS patients and healthy controls. Post-hoc comparisons were carried out using Scheffe's test. Association between ordinal and continuous variables was tested by linear regression models. A general linear model was applied to estimate the effect of both continuous and categorical variables in a multivariate setting. All analyses were performed using Statistica 7.0 software (Statsoft Inc., Tulsa, OK, USA) and Microsoft Excel 2000 (Microsoft Inc., Redmond, WA, USA).
Results
Flow cytometry analysis of CEC
Flow cytometry analysis was performed in 128 MDS patients (96 at diagnosis and 32 during the course of the disease) as well as in 28 healthy subjects. Analysis of CEC level was carried out comparing MDS patients at diagnosis with healthy controls; a comparison between MDS subgroups was also performed considering WHO and IPSS categories. An increased number of CECs was observed in MDS patients compared with healthy controls (Po0.001) ( Table 2 and Figure 3a) . To evaluate the effect of diagnosis on CECs, an analysis of variance was performed comparing patients with bone marrow blasts o5% (refractory anemias and cytopenias and MDS with del(5q), grouped as 'low-risk MDS'), refractory anemia with excess of blast (RAEB)-1 and RAEB-2 patients. A significant effect of WHO diagnosis on CEC levels was noticed (P ¼ 0.01), patients with low-risk MDS presenting the highest values (Table 2 and Figure 3a ). Patients with low-risk MDS showed significantly higher CEC level than healthy subjects, while only a borderline significance (P ¼ 0.053) was noticed in RAEB-1 patients and no significant difference was present between RAEB-2 patients and controls (Table 2) . A significant negative correlation was found Table 2 Circulating endothelial cell level and CEC ratio in MDS patients evaluated at diagnosis and in healthy controls Figure 3b ), CEC levels decreasing with the increase in IPSS risk. To assess the effect of time of evaluation on CEC level in low-risk patients, we carried out a linear regression analysis testing the association between CEC number and the time of evaluation from diagnosis: a significant negative correlation was noticed between CEC level and the duration of the disease (r ¼ À0.64, Po0.001; Figure 3c ), independent of IPSS progression. We calculated an immature-to-mature endothelial cell ratio (CEC ratio), based on the expression of CD133 (which is present in endothelial progenitor cells and lost during differentiation), and defined as the ratio between the percentage of CD146 þ / CD34 þ /CD45À/CD133 þ and CD146 þ /CD34 þ /CD45À/ CD133À cells. CEC ratio was higher in MDS patients than in healthy subjects (Po0.001; Table 2 ). Among MDS subgroups, analysis of variance showed that patients with low-risk MDS presented higher CEC ratio with respect to RAEB subjects (P ¼ 0.02), while CEC ratio in RAEB-1 and RAEB-2 patients was comparable to controls (Table 2) . Focusing the analysis on disease phase, a higher CEC ratio was found at diagnosis in comparison with patients evaluated in a later phase of the disease (CEC ratio 0.73, range 0-3.12 vs 0.21, range 0-0.54, respectively; Po0.001). In vitro CFU-EC and ECFC production, and cytogenetic and PCR analysis
Isolation, immunocytochemical characterization and FISH analysis of CEC
In vitro CFU-EC production was evaluated in 27 MDS patients (11 RA/RARS, 8 RCMD/RCMD-RS, 5 MDS with del(5q) and 3 RAEB-1), and compared with a group of 7 healthy subjects. In the great majority of MDS patients (22 subjects), there was no evidence of CFU-EC production after 10 days of culture, while in five patients, we detected 11, 4, 3, 2 and 1 CFU-EC colonies, respectively (mean frequency 0.77 per 10 6 MNC, 2.07 s.d.). The mean number of CFU-ECs observed in healthy subjects group was 19.85 per 10 6 MNCs plated (7.24 s.d.; Figure 2b ). In vitro ECFC production was evaluated in 13 MDS patients In comparison with healthy controls, MDS patients presented a decreased ability to form CFU-ECs (Po0.001), while in vitro ECFC production was significantly increased (P ¼ 0.031; Figure 2b ). In 11 MDS patients in which production of both CFU-ECs and ECFCs was assessed, we tested the correlation between circulating endothelial progenitor cells and the number of endothelial colonies. A positive correlation was found between circulating endothelial progenitor cell level and the number of ECFCs (r ¼ 0.56, P ¼ 0.021), while no significant relationship was found with the number of CFU-ECs (r ¼ 0.27, P ¼ NS).
Colony forming-unit-endothelial cells and ECFCs were isolated from three and four patients respectively with evidence of clonal chromosomal abnormalities in hematopoietic compartment (del5q31 in three cases, trisomy 8 in two cases and del7q31 in two cases) and tested for FISH analysis. In all cases, there was no evidence of chromosomal abnormalities in endothelial cells. In two cases (one with del5q31 and one with trisomy 8), chromosomal abnormality was found in immunomagnetically sorted CECs (60 and 39%, respectively, see above) but not in CFU-EC and ECFC colonies (Figure 4c ). Finally, in three endothelial colonies obtained from two MDS patients with del(5q), DNA was isolated and tested for the presence of chromosomal abnormality. Genotyping of polymorphic loci using DNA of the selected colonies showed the presence of two normal alleles as for the PB DNA, thus excluding the presence of deletions of the region 5q31.
Bone marrow microvessel density
Microvessel density was assessed in 78 MDS patients as well as in 12 control subjects. MDS patients showed significantly increased bone marrow MVD in comparison with controls (median 7, range 2-19, vs 4, range 2-5; P ¼ 0.009). This difference was noticed in all WHO categories (P ¼ 0.002, 0.012 and 0.027 in MDS o5% marrow blasts, RAEB-1 and RAEB-2, respectively), subjects with low-risk MDS showing the highest MVD level (median 8, range 2-19). Only a mild positive correlation was observed between MVD and CECs in all MDS patients (r ¼ 0.44, P ¼ 0.001). Considering MDS subgroups, this correlation was found to be strong in low-risk MDS (r ¼ 0.62, Po0.001; Figure 3d ), while it was not statistically significant in RAEB-1 and RAEB-2 categories (data not shown).
Discussion
Several evidences indicate that in MDS, the generation of new vessels is mandatory to the multistep process of conversion from normal to dysplastic bone marrow and ultimately to disease progression. [13] [14] [15] Recently, List et al. 29 reported remarkable clinical results with lenalidomide, which has been suggested to restore survival signals from the marrow microenvironment on hematopoietic precursors by modulating cytokine networks and by acting as a multifactorial inhibitor of angiogenesis.
In this study, we found that patients with MDS have increased level of CECs, and that this was particularly true for subjects without excess of blasts. This was mainly determined by reduced numbers of CD133 þ endothelial progenitors cells in patients with excess of blasts. We also observed a significant effect of disease duration on CECs. In fact, CEC levels were significantly higher in patients at diagnosis than in individuals at follow-up, the latter presenting a reduction of immature CD146 þ /CD133 þ endothelial compartment. Taken together, these results suggest that in MDS, the mobilization of endothelial cells in the bone marrow could be stage dependent, that is, increased in the first phases and gradually decreasing during the progression of the disease. 27 This agrees with the observation that marrow-derived endothelial cells contribute to the transformation of dormant to rapidly growing tumors most during the early phases of this process. 4, 5 Whether mobilized endothelial cells are functionally active and can be incorporated into the vascular bed in MDS remains to be clarified. Previous studies reported an increased bone marrow angiogenesis in both low-and high-risk MDS as well as at progression into overt acute leukemia. 14, 15 We observed a direct relationship between CECs and bone marrow vascularity in low-risk MDS, possibly indicating an active role of CEC mainly in the early phases of the disease. To determine the possible contribution of CECs to myelodysplastic bone marrow angiogenesis, we studied the proliferative potential of these cells. Recently, it was clarified that, similar to hematopoietic stem cell compartment, a hierarchy based on difference in proliferative potential is also present in endothelial progenitor cells. [25] [26] [27] [28] CFU-ECs, which coexpress hematopoietic and endothelial cell antigens, display a limited endothelial proliferative potential and possess myeloid progenitor cell activity. In contrast, ECFCs have an extensive endothelial proliferative potential and form perfused vessels in vivo. 30 We found that MDS presented a decreased ability to form CFU-ECs in comparison with healthy controls, while ECFC production was significantly increased and positively correlated with the number of circulating endothelial progenitor cells assessed by flow cytometry. It has been suggested that CFU-ECs are probably derived from the hematopoietic system. 30 In this light, a reduced production of these colonies is not surprising in MDS, which are characterized by defective in vitro growth capacity of hematopoietic progenitors. 11 On the other hand, the results of ECFC assays suggest that endothelial progenitor cells in PB of MDS patients might actively contribute to bone marrow angiogenesis. The positive correlation between CECs and ECFCs as well as MVD suggests that CECs are part of the tumor microenvironment in MDS.
An interesting finding of some studies is that CECs are at least in part tumor-related, suggesting a close association between the malignant clone and the endothelial compartment. 9, 10 In chronic myeloid leukemia, Fang et al. 10 identified a human progenitor cell carrying the BRC-ABL fusion gene with hemangioblastic characteristics, able to differentiate into malignant blood cells as well as into phenotypically defined endothelial cells. In MDS patients, we found the same chromosomal aberrations as the malignant hematopoietic cells in a proportion of CECs. According to this observation, angiogenic factors secreted into the myelodysplastic microenvironment might actively recruit bone marrow hemangioblasts and induce them to differentiate into hematopoietic and endothelial precursors. 32 It is well known, however, that cellular expression of endothelial markers and endothelial growth factor receptors is not restricted to proliferating endothelial cells but is also demonstrable in hematopoietic cells. 1, 2, 33 Moreover, disguised immature myelodysplastic hematopoietic cells could mimic the phenotype and function of endothelial cells. 3, 34 The expression of CD34 and VEGFR-2 as well as CD133 is shared by hematopoietic precursors or blasts 31, 33 but these cells express the hematopoietic lineage-specific antigen CD45 and are usually negative for most of the endothelial markers including CD146, von Willebrand factor and CD31. In addition, the production of endothelial colonies with a great proliferative potential is restricted to CD34 þ CD45À compartment that is devoid of hematopoietic activity. 33 All these data suggest that circulating CD146 þ CD34 þ CD45À cells are endothelial cells.
When we tested endothelial cells isolated from in vitro assays, we found that they were negative for the chromosomal abnormality of the malignant clone. There are different possible explications of these apparently conflicting findings. It is possible that the presence of chromosomal aberration is not compatible with the in vitro growth of the endothelial progenitor cells or that tumor-derived endothelial progenitor cells exist but are present in the PB at such a low frequency that they cannot be detected in our assay. Alternatively, according to the observation that in myeloproliferative diseases the V617F JAK2 mutation is present in hematopoietic-derived CFU-ECs but not in ECFCs, 31 and that coinjection of early and late outgrowth colony-forming cells synergistically improves neurovascularization in mice, 35 it can be speculated that in MDS, karyotypically normal endothelial progenitor cells directly contribute to neoangiogenesis process through the formation of new vessels, while clonal-derived hematopoietic myeloid progenitor cells may facilitate neoangiogenesis without directly participating in this process by promoting the mobilization of normal bone marrow endothelial progenitor cells. 36, 37 In conclusion, this study suggests that CECs reflect the abnormal angiogenesis found in the bone marrow of patients with low-risk MDS, especially in the early stages of the disease. No definitive evidence was provided whether these endothelial cells carry the same chromosomal abnormalities as the malignant cells. The increased number of functional endothelial progenitor cells in MDS strengthens the rationale for therapeutic interventions aimed at restoring a normal interaction between hematopoietic progenitors and marrow microenvironment. The ready accessibility of CEC quantitation by flow cytometry might help the evaluation of disease activity, and possibly the monitoring of clinical response during therapies that target angiogenesis.
